Geriatric Assessment and Technology Evaluation in Prostate Cancer
NCT06215508
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
By doing this study, doctors hope to learn more about factors that contribute to frailty (a condition where older adults feel weak, get tired easily, and struggle more with everyday activities) and serious side effects among men over the age of 65 who will receive androgen deprivation therapy (also called "hormone therapy") for prostate cancer that has spread to other parts of their body. Participation in this research will last about 5 years. For the first year, participants will have 5 study visits where they have give blood samples, answer survey questions, and use a wearable device.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Prostate Cancer
- Prostate Cancer Metastatic
Eligibility basics and study details
- Study type
- Observational
- Phase
- Not applicable
- Ages
- 18 Minutes and older
- Sex
- Male
- Healthy volunteers
- Not accepted
- Sponsor
- University of Chicago
- Last updated on ClinicalTrials.gov
- June 8, 2025
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Illinois · 1
- o University of Chicago Medicine Comprehensive Cancer Center · Chicago, IL
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.